NMDA receptor antagonists ketamine and Ro25-6981 inhibit evoked release of glutamate in vivo in the subiculum

Preclinical and clinical data have identified ketamine, a non-selective NMDAR (N-methyl-D-aspartate receptor) antagonist, as a promising medication for patients who do not respond to treatment with monoamine-based antidepressants. Moreover, unlike the current monoamine-based antidepressants, ketamin...

Descripción completa

Detalles Bibliográficos
Autores principales: Stan, T L, Alvarsson, A, Branzell, N, Sousa, V C, Svenningsson, P
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Nature Publishing Group 2014
Materias:
Original Article
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4080320/
https://www.ncbi.nlm.nih.gov/pubmed/24893066
http://dx.doi.org/10.1038/tp.2014.39

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4080320/
https://www.ncbi.nlm.nih.gov/pubmed/24893066
http://dx.doi.org/10.1038/tp.2014.39

Ejemplares similares